Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Classical hematology 3Myeloid 2

Conditions

Thrombocytopenia 5Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Sarcoma 1Purpura, Thrombocytopenic, Idiopathic 1Myeloproliferative Disorders 1Leukemia 1Jacobs syndrome 1Healthy Adults 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × eltrombopag × Clear all
NCT01957176 2022-12-30

A Rollover Study to Provide Continued Treatment With Eltrombopag

Novartis

Phase 4 Completed
22 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myeloid, Acute, Purpura, Thrombocytopenic, Idiopathic

NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Novartis

Phase 2 Completed
148 enrolled 42 charts
Classical hematologyOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT01440374 2017-06-05

ASPIRE

Novartis

Phase 2 Completed
162 enrolled 24 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡